To determine the proportion of patients who might 1) benefit from high-dose INH and/or 2) harbor resistance to ethionamide, we retrospectively reviewed the results of LPAs performed at the TB reference laboratory for KwaZulu-Natal province and calculated the relative proportions of patients with katG and/or inhA promoter mutations. This evidence concerns the gene INHA and tuberculosis.